Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-09T19:56:07.782Z Has data issue: false hasContentIssue false

111 - Pregabalin

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Lyrica, Zeegap

Generic?

• No

Class

• Antiepileptic drug (AED)

Commonly Prescribed for

(FDA approved in bold)

Partial-onset seizures (adjunctive for adults)

Neuropathic pain associated with post-herpetic neuralgia

Neuropathic pain associated with diabetic peripheral neuropathy

Neuropathic pain associated with spinal cord injury

Fibromyalgia

• Facial pain

• Panic disorder

• Mania or bipolar disorder

• Generalized anxiety disorder

• Alcohol/benzodiazepine withdrawal

How the Drug Works

• Structural analog of GABA that binds at the α2δ subunit of calcium channel (CACNA2D1) and reduces calcium influx. Modulates calcium channel function but not a channel blocker

• Reduces release of excitatory neurotransmitters, such as glutamate, norepinephrine, and substance P

• Inactive at GABA receptors and does not affect GABA uptake or degradation

How Long Until It Works

• Seizures: 2 weeks

• Pain/anxiety: days to weeks

• Fibromyalgia: often in the first week

If It Works

• Seizures: goal is the remission of seizures. Continue as long as effective and well tolerated. Consider tapering and slowly stopping after 2 years without seizures, depending on the type of epilepsy

• Pain: goal is reduction of pain. Usually reduces but does not cure pain and there is recurrence off the medication. Consider tapering for conditions that may improve over time, e.g., post-herpetic neuralgia or fibromyalgia

If It Doesn't Work

• Epilepsy: consider changing to another agent, adding a second agent, using a medical device, or a referral for epilepsy surgery evaluation. When adding a second agent, keep drug interactions in mind

• Pain: if not effective in 2 months, consider stopping or using another agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Epilepsy: no major drug interactions with other AEDs. Using in combination may worsen CNS side effects or weight gain

• Neuropathic pain: TCAs, AEDs (gabapentin, pregabalin, carbamazepine, lamotrigine), SNRIs (duloxetine, venlafaxine, milnacipran, mirtazapine, bupropion), capsaicin, and mexiletine are agents used for neuropathic pain. Opioids (morphine, tramadol) may be appropriate for long-term use in some cases but require careful monitoring. Proven to decrease opioid requirements in patients with post-herpetic neuralgia

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 410 - 413
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Pregabalin
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.112
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Pregabalin
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.112
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Pregabalin
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.112
Available formats
×